<DOC>
	<DOCNO>NCT00991744</DOCNO>
	<brief_summary>- Replacement intrathecal Triple ( methotrexate , cytarabine , prednisolone ) intrathecal liposomal cytarabine prednisolone maintenance therapy decrease CNS relapse rate high-risk ALL patient . - Both acute long-term toxicity equal treatment arm .</brief_summary>
	<brief_title>Liposomal Cytarabine Central Nervous System ( CNS ) -Treatment High-risk Acute Lymphoblastic Leukemia ( ALL )</brief_title>
	<detailed_description>20 % child ALL still fail cure . The ALL-2008 protocol treatment research protocol aim improve overall outcome Nordic child adolescents ALL comparison ALL-2000 protocol previous NOPHO protocol . The specific primary objective randomise study : 1 . To replace intrathecal triple ( methotrexate , cytarabine glucocorticosteroid ) intrathecal liposomal cytarabine glucocorticosteroid maintenance therapy order decrease central nervous system relapse rate high-risk acute lymphoblastic leukemia patient . 2 . To evaluate acute long-term toxicity treatment arm .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Cortisone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Cortisone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>High risk acute lymphoblastic leukemia Not eligible bone marrow transplantation Age 118 Written inform consent obtain Persistent NCI grade 34 neurotoxicity previous treatment Bilineage ALL Leukemia predispose syndrome ( e.g . Downs syndrome , Ataxia Telangiectasia ) Previous cancer Known intolerance NOPHO ALL 2008 anticancer agent Sexually active female use safe contraceptive Previous treatment intrathecal liposomal cytarabine</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Central nervous system</keyword>
	<keyword>Neurotoxicity</keyword>
	<keyword>Liposomal cytarabine</keyword>
	<keyword>Children</keyword>
	<keyword>Acute lymphoblastic leukemia</keyword>
	<keyword>Childhood acute lymphoblastic leukemia</keyword>
	<keyword>Intrathecal</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Safety</keyword>
</DOC>